间充质干细胞治疗COVID诱导的急性呼吸窘迫综合征的现状
Current Landscape of Mesenchymal Stem Cell Therapy in COVID Induced Acute Respiratory Distress Syndrome
摘要:
2019年底在中国湖北地区爆发的严重急性呼吸系统综合征冠状病毒2现已造成全球大流行,并已蔓延至150多个国家。在大多数人中,COVID 19是一种呼吸道感染,会引起发烧、咳嗽和呼吸急促。患有严重COVID 19的患者可能会发展为ARDS。MSC可以来自许多地方,如骨髓、脐带和脂肪组织。骨髓间充质干细胞因其易获得性和低免疫原性而被广泛应用于动物和临床研究。在最近的研究中,MSC已被证明可以减少炎症,增强肺渗透性,改善微生物和肺泡液清除,并加速肺上皮和内皮修复。此外,基于MSC的治疗在败血症和ARDS的临床前研究和I期临床试验中显示出有希望的结果。在本文中,我们介绍了使用MSC的治疗策略,并剖析了MSC治疗如何以及为什么是COVID 19诱导的ARDS的潜在治疗选择。我们引用了大量有前景的临床试验,阐明了MSC治疗COVID 19 ARDS患者的潜在优势,检查了这种治疗策略的效果,并提出了后续研究的可能性。
英文摘要:
The severe acute respiratory syndrome coronavirus 2 outbreak in Chinas Hubei area in late 2019 has now created a global pandemic that has spread to over 150 countries. In most people, COVID 19 is a respiratory infection that produces fever, cough, and shortness of breath. Patients with severe COVID 19 may develop ARDS. MSCs can come from a number of places, such as bone marrow, umbilical cord, and adipose tissue. Because of their easy accessibility and low immunogenicity, MSCs were often used in animal and clinical research. In recent studies, MSCs have been shown to decrease inflammation, enhance lung permeability, improve microbial and alveolar fluid clearance, and accelerate lung epithelial and endothelial repair. Furthermore, MSC-based therapy has shown promising outcomes in preclinical studies and phase 1 clinical trials in sepsis and ARDS. In this paper, we posit the therapeutic strategies using MSC and dissect how and why MSC therapy is a potential treatment option for COVID 19 induced ARDS. We cite numerous promising clinical trials, elucidate the potential advantages of MSC therapy for COVID 19 ARDS patients, examine the detriments of this therapeutic strategy and suggest possibilities of subsequent research.
机构、总结、中文摘要均由AI分析而来,可能存在错误,请以论文正文为准。